Jane Wasman
Chairman chez SELLAS LIFE SCIENCES GROUP, INC.
Fortune : 121 715 $ au 31/03/2024
Profil
Jane Wasman is currently the Chairman at Sellas Life Sciences Group Ltd., the Independent Chairman at SELLAS Life Sciences Group, Inc., the Independent Director at Rigel Pharmaceuticals, Inc., and the Director at Biotie Therapies Oy.
Previously, she served as the Chairman at SELLAS Life Sciences Group, Inc., the Chairman at Athersys, Inc., the Director at Cytovia Therapeutics, Inc., the Director at New York Biotechnology Association, Inc., the Staff Vice President & Associate General Counsel at Schering-Plough Corp., the Secretary & President-International at Acorda Therapeutics, Inc., the Associate General Counsel-Veteran Affairs at United States Senate, and the President, Secretary & General Counsel at Acorda Therapeutics Ltd.
Ms. Wasman received her undergraduate degree from Princeton University and her graduate degree from Harvard Law School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/01/2024 | 75 000 ( 0,04% ) | 111 000 $ | 31/03/2024 | |
| 22/01/2024 | 10 400 ( 0,02% ) | 10 504 $ | 31/03/2024 | |
ATHERSYS, INC.
0,06% | 14/08/2023 | 35 141 ( 0,06% ) | 211 $ | 31/03/2024 |
Postes actifs de Jane Wasman
| Sociétés | Poste | Début |
|---|---|---|
| BIOTIE THERAPIES CORP | Director/Board Member | 01/05/2016 |
| SELLAS LIFE SCIENCES GROUP, INC. | Chairman | 29/12/2017 |
| RIGEL PHARMACEUTICALS, INC. | Director/Board Member | 26/03/2019 |
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Chairman | 29/12/2017 |
Anciens postes connus de Jane Wasman
| Sociétés | Poste | Fin |
|---|---|---|
| ATHERSYS, INC. | Chairman | 01/04/2024 |
| ACORDA THERAPEUTICS, INC. | General Counsel | 31/12/2019 |
Acorda Therapeutics Ltd.
 Acorda Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Acorda Therapeutics Ltd. operates as a biopharmaceutical company. It manufactures pharmaceutical preparations and performs research and experimental development. The company was incorporated on March 03, 2009 and is headquartered in London, the United Kingdom. | President | 01/12/2019 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | 01/01/2004 |
Cytovia Therapeutics, Inc.
 Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Director/Board Member | - |
Formation de Jane Wasman
| Princeton University | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| ATHERSYS, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
New York Biotechnology Association, Inc.
 New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY. | Commercial Services |
| United States Senate | Government |
SELLAS Life Sciences Group, Inc. /Old/
 SELLAS Life Sciences Group, Inc. /Old/ BiotechnologyHealth Technology SELLAS Life Sciences Group, Inc. /Old/ is based in New York, NY. SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company. | Health Technology |
Acorda Therapeutics Ltd.
Acorda Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Acorda Therapeutics Ltd. operates as a biopharmaceutical company. It manufactures pharmaceutical preparations and performs research and experimental development. The company was incorporated on March 03, 2009 and is headquartered in London, the United Kingdom. | Health Technology |
| SELLAS Life Sciences Group, Inc. | |
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Health Technology |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
